Additionally, the biotech company anticipates per-share earnings of $5.50 to $5.70 on net sales of $10.5 billion to $11 billion for 2015, compared to average analyst forecasts of $5.68 per-share profit on revenue of $11.14 billion.
The company will release fourth quarter results on January 28.
The Qiagen (NasdaqGS: QGEN) was also among the worst performers in the biotech space after the genetic testing specialist missed its own forecast for sales and profits last year, especially after accounting for foreign exchange rates and the stronger U.S. dollar, Reuters reports. QGEN declined 12.1% Monday.
iShares Nasdaq Biotechnology ETF
Max Chen contributed to this article.